# Roisin E. O’Cearbhaill

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/roisin-e-o-cearbhaill/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,761 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 39 |
| i10-index | 111 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5053852463 |
| ORCID iD | 0000-0001-8217-4554 |
| Works | 412 |

## Researcher papers

- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-advanced-endometrial-cancer/)
- [A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab](https://scholariq.org/papers/a-phase-i-trial-of-regional-mesothelin-targeted-car-t-cell-therapy-in-patients/)
- [A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer](https://scholariq.org/papers/a-phase-i-clinical-trial-of-adoptive-t-cell-therapy-using-il-12-secreting-muc/)
- [Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial](https://scholariq.org/papers/olaparib-and-specific-pi3k-inhibitor-alpelisib-for-patients-with-epithelial/)
- [Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer](https://scholariq.org/papers/clinical-utility-of-prospective-molecular-characterization-in-advanced/)
- [Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/niraparib-first-line-maintenance-therapy-in-patients-with-newly-diagnosed/)
- [Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)](https://scholariq.org/papers/phase-ii-evaluation-of-nivolumab-in-the-treatment-of-persistent-or-recurrent/)
- [Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study](https://scholariq.org/papers/secondary-cytoreduction-and-carboplatin-hyperthermic-intraperitoneal/)
- [Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center](https://scholariq.org/papers/neoadjuvant-chemotherapy-and-primary-debulking-surgery-utilization-for-advanced/)
- [Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/efficacy-and-safety-of-niraparib-in-patients-aged-65-years-and-older-with/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.